French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
Category: #health  By Pankaj Singh  Date: 2020-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company has raised a total of USD 22.2 million.

The new funding round, which is the first after the last fundraising round in 2017, has been able to capture the attention of new investors, acquiring a further capital increase of USD 15.5 million. Moreover, the biotech company will receive an amount of USD 6.8 million in loans and subsidies from the region of Wallonia located in Belgium. Apparently, the region has backed the company since it started its operations there, in 2016.

As per sources close to the matter, PDC*line Pharma has attracted 5 new investors-  two Belgian funds, Sambrinvest (the investment fund of Charleroi) and SRIW (The Regional Investment Company of Wallonia), Korean Investment Partners( the leading multi-billion dollar South-Korean fund) and  two further South-Korean funds, UTC 2019 BIOVENTUREFUND and Shinhan-Cognitive Start-up Fund.

These new investors will be joining the company’s historical investors, which include SFPI-FPIM, Investment Company, the Belgian Federal Holding, Noshaq Group (ex-Meusinvest), a group of international business angels, the INVESTSUD Group/ Financière Spin-off Luxembourgeoise, and renowned entrepreneurs.

Eric Halioua, President & Chief Executive Officer of PDC*line Pharma was reportedly quoted saying that the company is humbled by the trust its investors have placed in them and the opportunity to successfully complete this fund raising.

Halioua further remarked that the competitive edge of the company’s vaccinal platform in cancer immunotherapy and the noteworthy achievements they have made over the last 3 years, including the start of phase I/II trials in Belgium and France in NSCLC  (non-small-cell lung cancer) and signing of a significant licensing deal with the Asian LG-Chem, have proved to be key factors, which have positively influenced investors’ decisions.

Source Credit: https://www.pdc-line-pharma.com/news/pdcline-pharma-raises-eu20-million-222m-series-b-financing-round

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...

Premier to buy two Greater New York Hospital Association subsidiaries
Premier to buy two Greater New York Hospital Association subsidiaries
By Pankaj Singh

Premier Inc., a renowned healthcare improvement company, has reportedly announced that it has entered a definitive agreement to purchase certain liabilities and all the assets of Nexera, Inc. and Acurity, Inc., two wholly owned indirect subsidiaries ...

Mitsubishi creates new technology to control in-building mobile robots
Mitsubishi creates new technology to control in-building mobile robots
By Pankaj Singh

Mitsubishi Electric Corporation has recently announced its technological development to control in-building mobile robots, by using building dynamic maps. This new 3D building map will show the status of mobilities within the building, including thei...